Literature DB >> 7164033

Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.

F A Ofosu, G Modi, A L Cerskus, J Hirsh, M A Blajchman.   

Abstract

Standard unfractionated heparin is known to have two actions on blood clotting. Unfractionated heparin enhances the rates at which antithrombin III inactivates activated clotting factors, and inhibits the activation of both Factor X and prothrombin by disrupting the calcium and phospholipid dependent assembly of the Factor X and prothrombin activator complexes. This latter inhibitory action of heparin occurs independently of antithrombin III. A heparin fraction with low affinity to antithrombin III was prepared from standard heparin by affinity chromatography on antithrombin-III-Sepharose and its properties compared with unfractionated heparin. The low affinity heparin fraction and the unfractionated heparin had equivalent inhibitory effects on prothrombin activation in antithrombin III depleted plasma. In normal plasma, the low affinity fraction inhibited the activation of prothrombin. Unlike the unfractionated heparin, however, the fraction of heparin with low affinity to antithrombin III did not enhance the inactivation of either Factor Xa or thrombin. This antithrombin III independent inhibition of the activation of prothrombin was also evident when activated platelets were used as the source of the procoagulant phospholipids. The antithrombin III independent effect of heparin is unlikely to be important therapeutically, however, if this property of heparin is shared by other naturally occurring glycosaminoglycans, it could be important in maintaining the fluidity of blood under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7164033     DOI: 10.1016/0049-3848(82)90165-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin.

Authors:  F A Ofosu; P Sie; G J Modi; F Fernandez; M R Buchanan; M A Blajchman; B Boneu; J Hirsh
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

2.  Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.

Authors:  F A Ofosu; G J Modi; M A Blajchman; M R Buchanan; E A Johnson
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

3.  Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses.

Authors:  B J Darien; J Potempa; J N Moore; J Travis
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

4.  ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

Authors:  I D Bradbrook; H N Magnani; H C Moelker; P J Morrison; J Robinson; H J Rogers; R G Spector; T Van Dinther; H Wijnand
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

5.  The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.

Authors:  T W Barrowcliffe; S J Havercroft; G Kemball-Cook; U Lindahl
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

Review 6.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

7.  Durable endothelium-mimicking coating for surface bioengineering cardiovascular stents.

Authors:  Qing Ma; Xiuying Shi; Xing Tan; Rui Wang; Kaiqin Xiong; Manfred F Maitz; Yuanyuan Cui; Zhangmei Hu; Qiufen Tu; Nan Huang; Li Shen; Zhilu Yang
Journal:  Bioact Mater       Date:  2021-05-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.